For informational and research purposes only. Not medical advice. Content is aggregated from public sources. Always consult a qualified healthcare provider.
Nootropic & Cognitive · Comparison

Cortexin vs Noopept

A neutral, side-by-side comparison of two nootropic & cognitive peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.

CortexinNoopept
CategoryNootropic & CognitiveNootropic & Cognitive
Also known ascortexin polypeptide, cortexin-10, neuropeptide bioregulator, cortexin-5GVS-111, N-phenylacetyl-L-prolylglycine ethyl ester, omberacetam, N-Phenylacetyl-L-Prolylglycine Ethyl Ester
EvidenceResearch-stageResearch-stage
Dosing range5mg–20mg mg, daily IM injection for 10-day courses5mg–20mg mg, 1–3x daily oral or sublingual (8–12 week cycles)
AdministrationIntramuscular injectionOral (capsule/powder), Sublingual (dissolved under tongue), Intranasal
Key side effectsInjection site pain, Rare allergic reaction, Headache (transient), Mild dizzinessHeadache (especially without choline supplementation), Irritability, Brain fog at high doses, Insomnia (if taken too late in day)
Cited sources2 references2 references

Key differences

  • Administration: Cortexin — Intramuscular injection; Noopept — Oral (capsule/powder), Sublingual (dissolved under tongue), Intranasal.
  • Frequency: Cortexin is typically daily IM injection for 10-day courses; Noopept is 1–3x daily oral or sublingual (8–12 week cycles).

How each works

Cortexin

Cortexin's multi-component neuropeptide mixture modulates neurotransmitter systems, improves cerebral blood flow, enhances neuroplasticity (BDNF upregulation), and exhibits antioxidant and anti-apoptotic activity in neuronal tissue. Russian stroke rehabilitation trials show improved neurological deficit scores and functional recovery with 10-day cortexin courses compared to standard care alone. The mechanism involves multiple parallel neuropeptide signaling pathways.

Noopept

Noopept (GVS-111) enhances AMPA-receptor function and increases expression of BDNF and NGF in the hippocampus and basal forebrain. Its active metabolite cycloprolylglycine acts as an endogenous neuropeptide with anxiolytic and cognition-enhancing properties. Russian clinical trials demonstrate cognitive improvement in subjects with cognitive impairment, with a better tolerability profile than piracetam at equipotent doses.

Read the full Cortexin profileRead the full Noopept profile

This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.